首页> 外国专利> METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE

METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE

机译:急性重症结肠炎治疗反应的预测方法

摘要

The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drag response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected front the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.
机译:本发明涉及用于预测急性重症结肠炎治疗反应的方法。目前,还没有拖拽反应的生物标志物。本发明提供了急性重症溃疡性结肠炎一线和二线治疗反应的第一个预测工具。从患者活检中确定了失调微RNA的假定mRNA靶点。一个由15个结肠微小RNA组成的分类器加上入院时的5个生物学值,用于区分类固醇的应答者和非应答者,预测准确率为96.6%。使用类似的方法,确定了6个和4个基于粘膜microRNA的算法,将应答者从英夫利昔单抗和环孢素的非应答者中分类。具体而言,本发明涉及通过测量从hp_hsa-mir-3934、hp_hsa-mir-100、hsa-mir-718、hp_hsa-mir-193b、hsa-mir-3150a-5p、hp_hsa-mir-1260b、hsa-mir-938、hsa-mir-518b和hsa-mir-1468组成的组中选择的几种miRNA的表达水平来预测急性重症结肠炎治疗反应的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号